S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

CAPR Capricor Therapeutics Inc

5.47

0.23 (4.39%)

May 03 2024 - Closed

Delayed by 15 minutes

Capricor Therapeutics GAAP EPS of -$0.26

To read the full story on Seeking Alpha, click here.

Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Capricor Therapeutics Charts.

Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Capricor Therapeutics Charts.

Capricor Therapeutics Inc News

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Wednesday 24 April 2024 (1 week ago) • GlobeNewswire Inc.

Capricor Therapeutics to Present at Upcoming Investor Conferences
Thursday 21 March 2024 (1 month ago) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Monday 11 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Thursday 29 February 2024 (2 months ago) • GlobeNewswire Inc.

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
Thursday 22 February 2024 (2 months ago) • GlobeNewswire Inc.

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
Tuesday 20 February 2024 (2 months ago) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Friday 16 February 2024 (3 months ago) • Edgar (US Regulatory)

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
Wednesday 24 January 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 11 January 2024 (4 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 4 January 2024 (4 months ago) • Edgar (US Regulatory)

More Capricor Therapeutics Inc News Articles

Bell Buckle (PK)

Umbra Applied Technologies (PK)

Code Green Apparel (PK)

Cann American (CE)

Marketing Worldwide (PK)

Moon Equity (PK)

Digital Brand Media and ... (PK)

Intergrated Cannabis Sol... (PK)

Hannover House (PK)

1812 Brewing (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions